Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

CAPS Rating: 1 out of 5

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.


Player Avatar zzlangerhans (99.85) Submitted: 2/11/2013 4:22:02 AM : Underperform Start Price: $6.43 SNSS Score: +12.44

The Sunesis seems to be rising again but it looks to me like a rising tide phenomenon. As I've said before, the requirement to increase enrollment after the interim analysis last September was the second worst possible outcome. VALOR is unlikely to return a positive result and there is absolutely no reason for the share price to be rising more than a year ahead of topline data. It seems the lessons of Celsion haven't been learned.

Featured Broker Partners